Page 1 | Search Results | Blood | American Society of Hematology

1-10 of 10

Sort by

Sort Order Select

Journal Articles

Long-Term Real-World Experience of CPX-351 in Combined French-Italian Cohorts Identified High Rate of Negative Measurable Residual Disease (MRD) and Prolonged Overall Survival

Blood (2023) 142 (Supplement 1): 4255.

https://doi.org/10.1182/blood-2023-177951

Published: 2023

Journal Articles

CPX-351 Induces Deep Response and Suppress the Impact of Poor Prognosis Mutations ( TP53, ASXL1, RUNX1 and EVI1 ) Defined By ELN-2017 in t-AML and MRC AML: A Report from a Multicentric French Cohort

Blood (2019) 134 (Supplement_1): 1355.

https://doi.org/10.1182/blood-2019-125623

Published: 2019

Journal Articles

Epstein-Barr Virus (EBV) Reactivation, Its Treatment with Rituximab and Their Impact on Relapse after Allogeneic Hematopoietic Stem Cell Transplantation for Hematological Malignancies

Mauricette Michallet, MD PhD, Mohamad Sobh, PharmD, Florence Ranchon, PharmD, Sandrine Leroy, MD, Fiorenza Barraco, MD, Xavier Thomas, MD PhD, Marie Balsat, MD, Caroline Lejeune, MD, Sophie Ducastelle, MD, Bruno Lina, MD PhD, Florence Morfin, MD, Myriam Renault, CRA, Florence Ader, MD, Catherine Rioufol, PharmD, Helene Labussiere, MD, Franck-Emmanuel Nicolini, MD PhD

Blood (2016) 128 (22): 3695.

https://doi.org/10.1182/blood.V128.22.3695.3695

Published: 2016

Journal Articles

Addition of More Immunosuppressive Drugs As Graft-Versus-Host Disease (GVHD) Prophylaxis Does Not Improve Gvhd Outcomes in Reduced Intensity Allogeneic Hematopoietic Cell Transplantation from Unrelated Donors

Mauricette Michallet, MD PhD, Mohamad Sobh, PharmD, Fiorenza Barraco, MD, Xavier Thomas, MD PhD, Marie Balsat, MD, Caroline Lejeune, MD, Sophie Ducastelle, MD, Myriam Renault, CRA, Nathalie Tedone, CRA, Helene Labussiere, MD, Franck-Emmanuel Nicolini, MD PhD

Blood (2016) 128 (22): 5786.

https://doi.org/10.1182/blood.V128.22.5786.5786

Published: 2016

Journal Articles

Optimizing the Outcomes of Allogeneic Hematopoietic Stem Cell (HSC) Transplantation for Hematological Malignancies: The Perfect Combination of Conditioning Regimen, Disease Stage and Type of HSC Donor

Mauricette Michallet, MD PhD, Mohamad Sobh, PharmD, Hélène Labussière-wallet, MD, Marie Balsat, MD, Caroline Lejeune, MD, Sophie Ducastelle-Leprêtre, MD, Fiorenza Barraco, MD, Xavier Thomas, Franck E. Nicolini, MD PhD

Blood (2015) 126 (23): 4324.

https://doi.org/10.1182/blood.V126.23.4324.4324

Published: 2015

Journal Articles

Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia Patients in First Complete Remission: Significant Impact of the Interval Between Diagnosis and Transplantation on Different Outcomes

Stéphanie Ducreux, PharmD, Mohamad Sobh, PharmD, Stéphane Morisset, Stat, Marie Balsat, MD, Xavier Thomas, Caroline Lejeune, MD, Sophie Ducastelle-Leprêtre, MD, Fiorenza Barraco, MD, Hélène Labussière-wallet, MD, Franck E. Nicolini, MD PhD, Mauricette Michallet, MD PhD, Valérie Dubois, MD

Blood (2015) 126 (23): 5517.

https://doi.org/10.1182/blood.V126.23.5517.5517

Published: 2015

Journal Articles

Survey of Serum Aspergillus Antigen in Patients Undergoing Chemotherapy for Acute Myeloid Leukemia or Allogeneic Hematopoietic Stem Cell Transplantation: Role in Predicting Invasive Aspergillosis and in Modifying the Therapeutic Strategy

Van Hung Tran, PhD, Florence Persat, MD, Sophie Gardes, MD, Jeremy Monfray, CRA, Sophie Ducastelle-Leprêtre, MD, Damien Dupont, Mohamad Sobh, PharmD, Fiorenza Barraco, MD, Hélène Labussière-Wallet, MD, Xavier Thomas, Franck E. Nicolini, MD PhD, Caroline Lejeune, MD, Marie Balsat, MD, René Ecochard, MD PhD, Mauricette Michallet, MD PhD

Blood (2015) 126 (23): 3428.

https://doi.org/10.1182/blood.V126.23.3428.3428

Published: 2015

Journal Articles

Allogeneic Hematopoietic Stem Cell Transplantation from Unrelated Peripheral Blood or Bone Marrow Donors: The Impact of HLA Matching Including HLA-DPB1 Allele in a Multivariable Risk Model

Mauricette Michallet, MD PhD, Mohamad Sobh, PharmD, Hélène Labussière-wallet, MD, Marie Balsat, MD, Caroline Lejeune, MD, Sophie Ducastelle-Leprêtre, MD, Xavier Thomas, Catherine Giannoli, Philippe Moskovtchenko, Tech., Fiorenza Barraco, MD, Franck E. Nicolini, MD PhD, Valérie Dubois, MD

Blood (2015) 126 (23): 3213.

https://doi.org/10.1182/blood.V126.23.3213.3213

Published: 2015

Journal Articles

First Results of a Prospective Study on Erythropoietin Biosimilar (Epoetin zeta) Use in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation for Hematological Malignancies

Mauricette Michallet, MD PhD, Mohamad Sobh, PharmD, Jeremy Monfray, CRA, Hélène Labussière-wallet, MD, Marie Balsat, MD, Caroline Lejeune, MD, Sophie Ducastelle-Leprêtre, MD, Fiorenza Barraco, MD, Xavier Thomas, Franck E. Nicolini, MD PhD

Blood (2015) 126 (23): 4477.

https://doi.org/10.1182/blood.V126.23.4477.4477

Published: 2015

Journal Articles

Mixed Chimerism at Three Months after Allogeneic Hematopoietic Stem Cell Transplantation Is a Significant Predictor of Disease Relapse in High-Risk Acute Myeloid Leukemia Patients in First Complete Remission

Mauricette Michallet, MD PhD, Mohamad Sobh, PharmD, Hélène Labussière-wallet, MD, Marie Balsat, MD, Caroline Lejeune, MD, Isabelle Mollet, Tech., Philippe Moskovtchenko, Tech., Xavier Thomas, Fiorenza Barraco, MD, Valérie Mialou, Tech., Valérie Dubois, MD, Franck E. Nicolini, MD PhD

Blood (2015) 126 (23): 2577.

https://doi.org/10.1182/blood.V126.23.2577.2577

Published: 2015

NARROW

Long-Term Real-World Experience of CPX-351 in Combined French-Italian Cohorts Identified High Rate of Negative Measurable Residual Disease (MRD) and Prolonged Overall Survival

CPX-351 Induces Deep Response and Suppress the Impact of Poor Prognosis Mutations ( TP53, ASXL1, RUNX1 and EVI1 ) Defined By ELN-2017 in t-AML and MRC AML: A Report from a Multicentric French Cohort

Epstein-Barr Virus (EBV) Reactivation, Its Treatment with Rituximab and Their Impact on Relapse after Allogeneic Hematopoietic Stem Cell Transplantation for Hematological Malignancies

Addition of More Immunosuppressive Drugs As Graft-Versus-Host Disease (GVHD) Prophylaxis Does Not Improve Gvhd Outcomes in Reduced Intensity Allogeneic Hematopoietic Cell Transplantation from Unrelated Donors

Optimizing the Outcomes of Allogeneic Hematopoietic Stem Cell (HSC) Transplantation for Hematological Malignancies: The Perfect Combination of Conditioning Regimen, Disease Stage and Type of HSC Donor

Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia Patients in First Complete Remission: Significant Impact of the Interval Between Diagnosis and Transplantation on Different Outcomes

Survey of Serum Aspergillus Antigen in Patients Undergoing Chemotherapy for Acute Myeloid Leukemia or Allogeneic Hematopoietic Stem Cell Transplantation: Role in Predicting Invasive Aspergillosis and in Modifying the Therapeutic Strategy

Allogeneic Hematopoietic Stem Cell Transplantation from Unrelated Peripheral Blood or Bone Marrow Donors: The Impact of HLA Matching Including HLA-DPB1 Allele in a Multivariable Risk Model

First Results of a Prospective Study on Erythropoietin Biosimilar (Epoetin zeta) Use in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation for Hematological Malignancies

Mixed Chimerism at Three Months after Allogeneic Hematopoietic Stem Cell Transplantation Is a Significant Predictor of Disease Relapse in High-Risk Acute Myeloid Leukemia Patients in First Complete Remission

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only